Superiority of pan-immune inflammation value, systemic inflammation index, and CALLY scores prognostic value for mortality of ischemic stroke patients followed in intensive care unit

dc.contributor.authorAltuntas, Gulsum
dc.contributor.authorYildirim, Rahmet
dc.contributor.authorDemirel, Ismail
dc.date.accessioned2026-08-12T17:11:06Z
dc.date.issued2025
dc.departmentFırat Üniversitesi
dc.description.abstractAims The Inflammatory response plays an important role in the pathophysiology and prognosis of ischemic stroke. Hyperinflammation progresses with aggravation of brain damage and deterioration in clinical status. The study aimed to demonstrate a valuable, easy-to-obtain, and inexpensive parameter for prognostic assessment by comparing the Pan-immune Inflammation Value (PIV), Systemic Immune-Inflammation Index (SII), and CALLY scores in patients with ischemic stroke. Methods In this retrospective single-center cohort study, the files of patients who were followed up with a diagnosis of ischemic stroke in the tertiary intensive care units. Multivariate regression analysis and receiver operating characteristic curves(ROC) were used to detect the association between PIV, SII, and CALLY on in-hospital mortality and their superiority over each other in predicting mortality in ischemic stroke patients. Results Of 1,039 patients, 453 died, resulting in an overall survival rate of 56.4%. In the multivariate analysis, high APACHE II scores and low albumin levels remained independent risk factors. ROC curves showed that PIV, SII, and CALLY exhibited good predictive values, with AUCs of 0.921, 0.887, and 0.930 (95% CI: 0.903-0.936, 0.855-0.896, 0.913-0.945; p < 0.001). A pairwise comparison of the data based on AUC values indicated a significant difference between SII and both PIV and CALLY (p < 0.001). In contrast, no significant difference was found between PIV and CALLY (p = 0.385). Conclusion The PIV, SII, and CALLY indices serve as accessible and reliable prognostic biomarkers that can enhance personalized treatment strategies and improve clinical decision-making in patients with ischemic stroke.
dc.identifier.doi10.1186/s12865-025-00730-7
dc.identifier.issn1471-2172
dc.identifier.issue1
dc.identifier.pmid40624614
dc.identifier.scopus2-s2.0-105010209988
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1186/s12865-025-00730-7
dc.identifier.urihttps://hdl.handle.net/11508/51027
dc.identifier.volume26
dc.identifier.wosWOS:001524214600002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectPan-immune-inflammation value
dc.subjectIschemic stroke
dc.subjectSystemic immune inflammation
dc.subjectInflammation biomarker
dc.subjectCALLY index
dc.titleSuperiority of pan-immune inflammation value, systemic inflammation index, and CALLY scores prognostic value for mortality of ischemic stroke patients followed in intensive care unit
dc.typeArticle

Dosyalar